Tay Salimullah

Tay Salimullah is a Venture Partner at 4BIO Capital® and Managing General Partner of Renovamen Advisory® LLC. With over 25 years in pharma, biotech, and MedTech, he specializes in advancing early-stage innovation and global access to genomic medicines. At Novartis Gene Therapies®, he helped lead the transformation of AveXis® into a global leader, driving Zolgensma® approvals across 55+ countries and enabling treatment for over 5,000 SMA patients. Earlier, he supported the launch of Kymriah®, the first FDA-approved CAR-T therapy, helping establish durable remission in pediatric leukemia. Tay’s expertise spans drug development, pricing science, and commercialization of complex modalities. He serves on the board and as Chief Strategy Officer of Trogenix®, focused on AAV-based oncology therapies. A Fellow of the Alliance for Regenerative Medicine®, Tay is a frequent contributor to global reimbursement panels and has authored perspectives in journals including Nature: Gene Therapy. His mission: to reimagine access not as an afterthought, but as a core driver of therapeutic innovation—especially in markets underserved by traditional biopharma models.